EpiEndo Pharmaceuticals
Manufacturing · Iceland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
13 Eiðistorg, Seltjarnarnes, Capital Reg...Phone Number
+354 4540090Website
www.epiendo.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About EpiEndo Pharmaceuticals
EpiEndo Pharmaceuticals is a clinical-stage pharmaceutical company developing a proprietary portfolio of drugs to address the huge global burden of chronic respiratory diseases. EpiEndo Pharmaceuticals is headquartered in Iceland, with a core team based across Iceland, Sweden, Germany, and the UK.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EpiEndo Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when EpiEndo Pharmaceuticals launches new products
Funding: Get notified immidiatlly once EpiEndo Pharmaceuticals has new funding data
Check out if EpiEndo Pharmaceuticals is spiking on competitors!
Click to see if EpiEndo Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on EpiEndo Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if EpiEndo Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
EpiEndo Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at EpiEndo Pharmaceuticals
Recommended Actions
Reach out to Masked Content who joined EpiEndo Pharmaceuticals as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
EpiEndo Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EpiEndo Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EpiEndo Pharmaceuticals.
EpiEndo Pharmaceuticals financials insights
Gather financial insights about EpiEndo Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Angel/Seed
$2.3M
2021
Series A
$23.4M
EpiEndo Pharmaceuticals Tech Stack
A closer look at the technologies used by EpiEndo Pharmaceuticals
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
EpiEndo Pharmaceuticals News & Media
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
REYKJAVIK, Iceland--(BUSINESS WIRE)--EpiEndo Pharmaceuticals has had clinical and preclinical data published in articles in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics.EpiEndo reports Phase 2A results for lead asset, EP395, in COPD
REYKJAVIK, Iceland--(BUSINESS WIRE)--EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). EP395 is the most advanced of EpiEndo’s orally available, non-antibiotic macrolides or ‘BarriolidEpiEndo commences Phase 2a trial for EP395 in COPD patients
REYKJAVIK, Iceland--(BUSINESS WIRE)--EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide™,’ with reduced antimicrobial resistance potential, which aims to address the unmet medical need for a treatmentEpiEndo commences LPS challenge trial for lead candidate EP395
REYKJAVIK, Iceland--(BUSINESS WIRE)--EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with lead molecule EP395. EP395 is an orally available macrolide or ‘Barriolide™‘ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for COPD (Chroni
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EpiEndo Pharmaceuticals
Sign Up For FreeTo access detailed company insights
EpiEndo Pharmaceuticals is a clinical-stage pharmaceutical company developing a proprietary portfolio of drugs to address the huge global burden of chronic respiratory diseases. EpiEndo Pharmaceuticals is headquartered in Iceland, with a core team based across Iceland, Sweden, Germany, and the UK.... Read More
